Drug General Information
Drug ID	D0Q0EF
Former ID	DNCL003122
Drug Name	ITI-007
Indication	Schizophrenia; Sleep maintenance insomnia [ICD9: 295, 307.41, 307.42, 327.0, 780.51, 780.52; ICD10:F20, F51.0, G47.0]		Phase 3	[525226], [549912]
Company	Intra-Cellular Therapies
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Sodium-dependent serotonin transporter	Target Info	Antagonist	[551041]
	5-hydroxytryptamine 2A receptor	Target Info	Antagonist	[551041]
KEGG Pathway	Serotonergic synapsehsa04020:Calcium signaling pathway
	Neuroactive ligand-receptor interaction
	Gap junction
	Serotonergic synapse
	Inflammatory mediator regulation of TRP channels
NetPath Pathway	TCR Signaling Pathway
PANTHER Pathway	5HT1 type receptor mediated signaling pathway
	5HT2 type receptor mediated signaling pathway
	5HT3 type receptor mediated signaling pathway
	5HT4 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathway
Reactome	Serotonin receptors
	G alpha (q) signalling events
WikiPathways	Monoamine Transport
	SIDS Susceptibility Pathways
	NRF2 pathway
	Synaptic Vesicle Pathway
	Serotonin Transporter ActivityWP733:Serotonin Receptor 2 and STAT3 Signaling
	Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
	Monoamine GPCRs
	GPCRs, Class A Rhodopsin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	GPCR ligand binding
	GPCR downstream signaling
	GPCRs, Other
References
Ref 525226	ClinicalTrials.gov (NCT02469155) A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment.
Ref 549912	Clinical pipeline report, company report or official report of Intra-Cellular Therapies.
Ref 551041	Clinical pipeline report, company report or official report of Intra-Cellular Therapies, Inc.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.